ライフサイエンスコーパス: biopharmaceutical

1 edefining, rebranding and co-opting what is 'biopharmaceutical'.

2 ng others, with diseases and the efficacy of biopharmaceuticals.

3 ing of mAb quality in process development of biopharmaceuticals.

4 y for FcRn, HSA is versatile as a carrier of biopharmaceuticals.

5 for analysis of serum half-life of HSA-based biopharmaceuticals.

6 red to promote binding and recovery of these biopharmaceuticals.

7 y be used for quality control of recombinant biopharmaceuticals.

8 n proteins, are a novel and growing class of biopharmaceuticals.

9 is critically important to the production of biopharmaceuticals.

10 ges, limiting their effective application as biopharmaceuticals.

11 t monoclonal IgG1 antibody, a major class of biopharmaceuticals.

12 detected modifications of well-characterized biopharmaceuticals.

13 monitoring conformational changes in protein biopharmaceuticals.

14 onoclonal antibodies are a major subclass of biopharmaceuticals.

15 stems for production of vaccine antigens and biopharmaceuticals.

16 ation has turned proteins into important new biopharmaceuticals.

17 cturing platform for the production of human biopharmaceuticals.

18 at engineered antibodies have come of age as biopharmaceuticals.

19 express high levels of vaccine antigens and biopharmaceuticals.

20 tructural biology and the development of new biopharmaceuticals.

21 uitable for the high-throughput screening of biopharmaceuticals.

22 in the clinical development of plant-derived biopharmaceuticals.

23 be exploited further in the design of novel biopharmaceuticals.

24 evading immune surveillance in the field of biopharmaceuticals.

25 DA-bound concentrations of all non-IgG-based biopharmaceuticals.

26 more common route for the administration of biopharmaceuticals.

27 n of disease states and the manufacturing of biopharmaceuticals.

28 es are currently the most important class of biopharmaceuticals.

29 s a rich source of known and potentially new biopharmaceuticals.

30 lonal antibodies (mAbs) are a major class of biopharmaceuticals.

31 ractive for improving the serum half-life of biopharmaceuticals.

32 ning the therapeutic outcomes of SC injected biopharmaceuticals.

33 on proteins (immunocytokines) are innovative biopharmaceutical agents, which are being considered for

34 able addition to the experimental toolbox of biopharmaceutical analysis.

35 is gaining high recent interest in both the biopharmaceutical and biomedical fields.

36 ocedure in view of the production of SLM for biopharmaceutical and biotech protocols.

37 Biopharmaceutical and biotechnology companies and regula

38 In addition to biopharmaceutical and industrial applications, stable pr

39 rotein acidostability is a common problem in biopharmaceutical and other industries.

40 (ELISA) is a widely used tool for analyzing biopharmaceutical and vaccine products.

41 Such biopharmaceuticals and edible vaccines can be stored and

42 eomics, during development and production of biopharmaceuticals and for the clinical analysis of glyc

43 pportunities for the optimization of protein biopharmaceuticals and for the development of cell-perme

44 mon chemical degradation pathway observed in biopharmaceuticals and is particularly prevalent in synt

45 a catalyst for the development of vaccines, biopharmaceuticals and small molecule therapeutics.

46 Biopharmaceuticals and small-molecule drugs have differe

47 are important to both the supply of marketed biopharmaceuticals and the pipelines of novel therapeuti

48 es may be very useful for quality control of biopharmaceuticals and their biosimilars.

49 ation and absolute quantification of protein biopharmaceuticals and their product-related impurities,

50 sialylated O-glycans most commonly found on biopharmaceuticals) and bovine submaxillary gland mucin

51 cterization and quality control step for any biopharmaceutical, and this is usually measured by fluor

52 ationship in the context of physicochemical, biopharmaceutical, and toxicological profiling.

53 ential, utility in large-scale production of biopharmaceuticals, and the capacity to act as probes to

54 vel has a great potential for biomedical and biopharmaceutical applications.

55 ational design methods for biotechnology and biopharmaceutical applications.

56 -specific reactive immunization, a potential biopharmaceutical approach to glycation-related patholog

57 Here, the data for biopharmaceuticals approved between 1995 and 1999 are pr

58 e clinical and approval phases of the 26 new biopharmaceuticals approved by the US Food and Drug Admi

59 Protein biopharmaceuticals are an important and growing area of

60 Protein-based biopharmaceuticals are becoming increasingly widely used

61 Monoclonal antibodies and recombinant DNA biopharmaceuticals are derived from relatively homogeneo

62 As many biopharmaceuticals are glycosylated in order to be funct

63 Biopharmaceuticals are making increasing impact on medic

64 As more protein biopharmaceuticals are produced using mammalian cell cul

65 nal antibodies, the fastest growing class of biopharmaceuticals, as well as membrane-associated and c

66 horesis and cIEF should be considered during biopharmaceutical assay development.

67 C to resolve hydrophilic variants of protein biopharmaceuticals at the middle-up level of analysis, i

68 tforms which will have significant impact in biopharmaceutical-based therapeutics.

69 Antibody fragments are emerging as promising biopharmaceuticals because of their relatively small siz

70 t and quality control of modern glycosylated biopharmaceuticals, but also in clinical biomarker disco

71 modular approach to append functionality to biopharmaceuticals by noncovalent modification with othe

72 s) are fundamental to the variability of the biopharmaceutical characteristics of drugs and to underl

73 Difficult biopharmaceutical characteristics of oligonucleotides, s

74 eotide using a brush polymer can improve its biopharmaceutical characteristics, including enzymatic s

75 areas of structural biology, biophysics, and biopharmaceutical characterization.

76 c antibodies and biosimilars, an appropriate biopharmaceutical CMC control strategy that connects cri

77 A key challenge for the academic and biopharmaceutical communities is the rapid and scalable

78 s medicines, have long provided value to the biopharmaceutical community as models of success, often

79 ed stocks, we track the performance of 1,066 biopharmaceutical companies from 1930 to 2015-the most c

80 A majority of the largest biopharmaceutical companies have announced strategic par

81 The performance of all biopharmaceutical companies is subject not only to facto

82 unding the risk and reward of investments in biopharmaceutical companies poses a challenge to those i

83 in which it established collaborations with biopharmaceutical companies to support early-stage effor

84 Support from major biopharmaceutical companies, development of hydroponic p

85 xperience as a portfolio manager in a larger biopharmaceutical company and the skills from academic r

86 creasingly used for the capture of different biopharmaceutical compounds within complex biological mi

87 The desire to deliver protein and peptide biopharmaceuticals conveniently and effectively has led

88 e system models environmental changes that a biopharmaceutical could experience as it transitions fro

89 precisely controlled release of SC injected biopharmaceuticals could be achieved.

90 Residual host cell proteins (HCPs) in biopharmaceuticals derived from recombinant DNA technolo

91 clinical trials are proceeding on the first biopharmaceuticals derived from them.

92 6 orders of magnitude less abundant than the biopharmaceutical-derived peptides.

93 a convenient quality examination tool during biopharmaceutical development and manufacturing processe

94 A major limitation in biopharmaceutical development is selectively targeting d

95 therefore offers significant advantages for biopharmaceutical development laboratories.

96 otential to benefit and accelerate the early biopharmaceutical development process, particularly by e

97 trifugation (SV-AUC) is routinely applied in biopharmaceutical development to measure levels of prote

98 In protein chemistry, proteomics and biopharmaceutical development, there is a desire to know

99 represent the dominant production hosts for biopharmaceutical development, yet the physiology of the

100 EGs), up to 40 kDa, typical of those used in biopharmaceutical development.

101 apeutic) proteins, which are widely used for biopharmaceutical development.

102 ant targets for fundamental research and for biopharmaceutical development.

103 nt for biomolecular research, diagnosis, and biopharmaceutical development.

104 t quality attribute that is monitored during biopharmaceutical development.

105 Anticalins are a novel class of biopharmaceuticals, displaying highly desirable attribut

106 ologies that are increasingly being used for biopharmaceutical drug discovery.

107 no association between drug lipophilicity or Biopharmaceutical Drug Disposition Classification System

108 is a critical attribute of any protein-based biopharmaceutical drug due to a protein's inherent tende

109 he antithrombin III (AT)-binding site in the biopharmaceutical drug heparin.

110 In recent years, biopharmaceutical drug products have become hugely succe

111 m may be in the high-throughput screening of biopharmaceutical drugs that are potential inhibitors of

112 ng remains a challenge in the formulation of biopharmaceuticals due to artifacts associated with each

113 ikelihood for such defects is heightened for biopharmaceuticals due to their complexity, which makes

114 for the enhanced characterization of complex biopharmaceuticals, especially those with charge and gly

115 n studies of skin-impermeant medications and biopharmaceuticals for clinical applications.

116 le method to examine the potential fate of a biopharmaceutical formulation after its SC injection in

117 d to anticipate the in vivo performance of a biopharmaceutical formulation intended for SC injection.

118 The rapid maturation of the field of biopharmaceutical formulation is the result of the simul

119 Movement of a biopharmaceutical from the injection chamber to the infi

120 components that may affect the release of a biopharmaceutical from the SC injection site.

121 ths that take place during the production of biopharmaceuticals from animal cell lines.

122 Along with the recent increase in biopharmaceutical funding in gene therapy, industry part

123 The correct glycosylation of biopharmaceutical glycoproteins and their formulations i

124 e SC tissue when formulating for SC injected biopharmaceuticals has improved the predictability of dr

125 , there is interest in implementing LC-MS in biopharmaceutical HCP profiling alongside conventional E

126 One transgenic plant-derived biopharmaceutical, hirudin, is now being commercially pr

127 thalmology is likely to involve the areas of biopharmaceuticals, implantable materials (e.g. tissue r

128 yield bioreactor for the production of human biopharmaceuticals in egg whites using genetic engineeri

129 yield bioreactor for the production of human biopharmaceuticals in egg whites.

130 d clinical development of safe and effective biopharmaceuticals in plant hosts.

131 MS) and (1)H NMR for the glycome analysis of biopharmaceuticals in research, development, and quality

132 They are structurally different from other biopharmaceuticals in size and quaternary structure.

133 gs, the conformational properties of protein biopharmaceuticals in solution are influenced by a varie

134 te, National Institutes of Health, and Eiger Biopharmaceuticals Inc.

135 eta4, ranging from 25 to 100 ng/ml (RegeneRx Biopharmaceuticals Inc., Rockville, MD), for 4 days.

136 heterologous proteins of high quality in the biopharmaceutical, industrial and academic environments.

137 apeutic glycoproteins has been emphasized in biopharmaceutical industries because the carbohydrate co

138 altered the nature of the biotechnology and biopharmaceutical industries.

139 aggregation is a significant problem in the biopharmaceutical industry (protein drug stability) and

140 tal to fulfill the contemporary needs of the biopharmaceutical industry and requirements of national

141 racentrifugation (SV-AUC) has emerged in the biopharmaceutical industry as a technique to detect smal

142 ibody (rMab) drugs is a major concern in the biopharmaceutical industry as it impacts the drugs' many

143 mass spectrometry can and should play in the biopharmaceutical industry beyond the presently assigned

144 rch efforts in academic institutions and the biopharmaceutical industry have become increasingly tran

145 f therapeutic and endogenous proteins in the biopharmaceutical industry over the past several years,

146 s, it becomes increasingly important for the biopharmaceutical industry to have tools to characterize

147 ectric focusing (cIEF) is widely used in the biopharmaceutical industry to measure the charge distrib

148 In the biopharmaceutical industry, elucidation of the cysteine

149 biosyntheses, once only in the realm of the biopharmaceutical industry, have now been embraced by th

150 Within the biopharmaceutical industry, recombinant plasmid DNA is u

151 duction of biologics, a growing trend in the biopharmaceutical industry, requires a reliable and effi

152 ectrophoresis in biomedical research and the biopharmaceutical industry, the development of data inte

153 For the protein biopharmaceutical industry, therefore, it is important t

154 Biologic drugs are promoting growth in the biopharmaceutical industry.

155 immune system and of vital importance in the biopharmaceutical industry.

156 tic antibodies is of great importance to the biopharmaceutical industry.

157 enteral administration are of concern in the biopharmaceutical industry.

158 ations (PTMs) of recombinant proteins in the biopharmaceutical industry.

159 proteins is of increasing interesting in the biopharmaceutical industry.

160 itor other attributes and applied across the biopharmaceutical industry.

161 es have become a major driving force for the biopharmaceutical industry; therefore, the discovery and

162 Chemical modifications on protein biopharmaceuticals introduce extra variability in additi

163 The manufacture of protein biopharmaceuticals is conducted under current good manuf

164 on of an expression platform for recombinant biopharmaceuticals is often centered upon suitable produ

165 the first time for in planta quantitation of biopharmaceuticals, is especially useful for insoluble o

166 odies is an area of significant focus in the biopharmaceutical landscape.

167 cal assets in the discovery and selection of biopharmaceutical lead candidates.

168 an orally, both of which suggest substantial biopharmaceutical liabilities.

169 res (Ethicon, NJ), Evicel fibrin glue (Omrix Biopharmaceuticals Ltd, Ramat-Gan, Israel), or Tisseel f

170 Biopharmaceutical manufacturing capacity has moved throu

171 Current biopharmaceutical manufacturing systems are not compatib

172 part of many industrial processes, including biopharmaceutical manufacturing.

173 Oxidation of biopharmaceuticals may affect their bioactivity, serum h

174 Here, a platform approach to biopharmaceutical modification is described that relies

175 ly monitoring the in vivo deamidation of the biopharmaceutical monoclonal antibody trastuzumab at a c

176 Some of the most expensive biopharmaceuticals of restricted availability, such as g

177 ajor costs associated with the production of biopharmaceuticals or vaccines in fermentation-based sys

178 mi-synthetic availability, purity and cost), biopharmaceutical (poor bioavailability and limiting pha

179 ic agents, and the characterization of these biopharmaceuticals poses a significant analytical challe

180 ly intended to address challenges arising in biopharmaceutical practice by promoting improved stabili

181 In biopharmaceutical process development, it is desirable t

182 The potential impact of transcriptomics on biopharmaceutical process technology is also discussed.

183 detection and monitoring of this epitope in biopharmaceuticals produced in recombinant mammalian sys

184 In some cases, delivery of a biopharmaceutical product by direct ingestion of the mod

185 l play an increasing role in next generation biopharmaceutical product characterization like bsAbs, a

186 ing protein aggregation at various stages of biopharmaceutical product design.

187 characterizing conformational changes in the biopharmaceutical product interferon beta-1a (IFN-beta-1

188 Development of biopharmaceutical production cell lines requires efficie

189 trate this, we de novo-created promoters for biopharmaceutical production in CHO cells that exhibited

190 n the early research and discovery phases of biopharmaceutical production.

191 omposite mixtures of antibodies representing biopharmaceutical products coexpressed from single cells

192 Characterization of biopharmaceutical products is a challenging task, which

193 e tool for characterization of heterogeneous biopharmaceutical products such as bispecific antibodies

194 with molecular biology to yield more than 40 biopharmaceutical products, such as erythropoietin, huma

195 ard" for subvisible particle measurements in biopharmaceutical products, the current technology has l

196 sed attention to quality by design (QbD) for biopharmaceutical products, there is a demand for accura

197 ualitative and semiquantitative profiling of biopharmaceutical products.

198 iseases to development of safe and efficient biopharmaceutical products.

199 The modified biopharmaceutical properties of 3 translated into excell

200 ce of the differing acyl groups on these key biopharmaceutical properties, confirming that acyl group

201 Chemical modification to improve biopharmaceutical properties, especially oral absorption

202 ally penetrant molecule which possesses good biopharmaceutical properties, is highly water-soluble, a

203 potency and unattractive pharmacological and biopharmaceutical properties.

204 g selectivity for JAK3 versus JAK1, and good biopharmaceutical properties.

205 explore novel TNIK inhibitors with desirable biopharmaceutical properties.

206 er systemic administration due to individual biopharmaceutical properties.

207 ormone-related adverse effects and improving biopharmaceutical properties.

208 considerable potential for the production of biopharmaceutical proteins and peptides because they are

209 Oral delivery of biopharmaceutical proteins expressed in plant cells shou

210 he simultaneous quantification of the 60-kDa biopharmaceutical proteins recombinant human tumor necro

211 haracterization and quantitative analysis of biopharmaceutical proteoforms.

212 vity levels realistic to the requirements of biopharmaceutical research and development.

213 ties thus providing valuable information for biopharmaceutical research and development.

214 e quality and quantity of pharmaceutical and biopharmaceutical research has changed.

215 easing attention in biological, medical, and biopharmaceutical research.

216 ble oral bioavailability of CsA represents a biopharmaceutical risk factor for the occurrence of chro

217 of oxidation in drug products containing the biopharmaceuticals Rituximab, Adalimumab, and Etanercept

218 To improve biopharmaceutical safety, we suggest transitioning their

219 pegfilgrastim batch was analyzed as a a real biopharmaceutical sample to confirm the feasibility of o

220 mance guidelines and applied to characterize biopharmaceutical samples, including IgG4 monoclonal ant

221 to detect low ppm levels of residual HCPs in biopharmaceutical samples.

222 mer's) but also due to its importance in the biopharmaceutical sector, where aggregation of protein t

223 ave application across both the chemical and biopharmaceutical sectors.

224 otide, and helps to overcome their intrinsic biopharmaceutical shortcomings, such as poor enzymatic s

225 g pathways is essential to the production of biopharmaceuticals since commercial production of recomb

226 xciting theoretical potential for converting biopharmaceutical strategies such gene correction and CR

227 timately resulted in the current experienced biopharmaceutical stronghold in the therapeutic market.

228 an be used for the production of recombinant biopharmaceuticals such as cytokines, hormones, monoclon

229 ant determinant of efficacy and clearance of biopharmaceuticals such as immunoglobulin G (IgG).

230 the most common route of self-administering biopharmaceuticals such as proteins and peptides.

231 rization using TERS, which would have use in biopharmaceutical synthesis and formulation research.

232 demonstrate the utility of the HBD of NRG in biopharmaceutical targeting and provide a new way to blo

233 utilized to extend the serum persistence of biopharmaceuticals that are fused to albumin.

234 ins (HCPs) are process-related impurities of biopharmaceuticals that remain at trace levels despite m

235 Biopharmaceuticals that target specific disease-mediatin

236 al of Chlamydomonas to produce a recombinant biopharmaceutical, the HIV antigen P24.

237 using a continuous process for production of biopharmaceuticals, the traditional bottom-up method, al

238 When used as biopharmaceutical therapeutics, such heterogeneities may

239 There is a need to improve delivery of biopharmaceuticals to enable less-invasive delivery rout

240 hould have general use as fusion partners to biopharmaceuticals to extend their half-lives in vivo.

241 Noncovalent binding of biopharmaceuticals to human serum albumin protects again

242 p controlled-release systems for delivery of biopharmaceuticals to the eye.

243 se traditional pharmaceuticals as opposed to biopharmaceuticals to treat single-gene disorders.

244 Plastid-made biopharmaceuticals treat major metabolic or genetic diso

245 een used to prolong the in vivo half-life of biopharmaceuticals, using the interaction with FcRn to i

246 the workflow by cloning 24 human proteins of biopharmaceutical value, either as direct therapeutics o

247 he potential to enhance the oral delivery of biopharmaceuticals via a transient regulation of an endo

248 recent advances in yeast-based expression of biopharmaceuticals will be discussed.

249 Moreover, HSA is a biopharmaceutical with a growing repertoire of putative

250 an interferon-beta1 (Avonex, rhIFN-beta1), a biopharmaceutical with complex glycosylation at a single

251 ing, purifying, and formulating a commercial biopharmaceutical with consistent therapeutic properties

252 dily supports large-scale glycan analysis of biopharmaceuticals with rapid deglycosylation times.

253 in biosensors), or as nonimmunogenic in vivo biopharmaceuticals with superior biodistribution and blo

254 ement allows for real-time monitoring of the biopharmaceutical within the injection chamber, and can